Warning: The NCBI web site requires JavaScript to function. more...
Safety concerns on the development of novel therapeutic drugs.
Ospelt C, Gay S.
Arthritis Res Ther. 2006;8(5):112.
Related citations
[Development of antituberculous drugs: current status and future prospects].
Tomioka H, Namba K.
Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.
Toxicogenomics in drug discovery and development -- making an impact.
Wills Q, Mitchell C.
Altern Lab Anim. 2009 Sep;37 Suppl 1:33-7.
[DNA microarrays--perspective of application for drug effectivity and safety evaluation].
Roman I.
Postepy Biochem. 2008;54(1):107-15. Review. Polish.
Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone.
Workman P.
Cancer Detect Prev. 2002;26(6):405-10. Review.
The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S45-56. Epub 2003 Jun 18. Review.
Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J.
Int J Clin Pharmacol Ther. 1999 Dec;37(12):575-83. Review.
Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
Serabian MA, Pilaro AM.
Toxicol Pathol. 1999 Jan-Feb;27(1):27-31. Review.
Novel molecular targets in cancer chemotherapy waiting for discovery.
Kunick C.
Curr Med Chem Anticancer Agents. 2004 Sep;4(5):421-3. Review.
New approaches and technologies in drug design and discovery.
Kleinberg ML, Wanke LA.
Am J Health Syst Pharm. 1995 Jun 15;52(12):1323-36; 1341-3. Review.
Recent progress in biomolecular engineering.
Ryu DD, Nam DH.
Biotechnol Prog. 2000 Jan-Feb;16(1):2-16. Review.
Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA.
Oncologist. 1996;1(3):II-III.
Personalised medicine for cancer: from drug development into clinical practice.
Jain KK.
Expert Opin Pharmacother. 2005 Aug;6(9):1463-76. Review.
Translational research in the pharmaceutical industry: from theory to reality.
Sultana SR, Roblin D, O'Connell D.
Drug Discov Today. 2007 May;12(9-10):419-25. Epub 2007 Apr 5. Review.
Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review.
Dietel M, Sers C.
Virchows Arch. 2006 Jun;448(6):744-55. Epub 2006 Apr 22. Review.
Advances in pharmacogenomics technologies.
Bhasker CR, Hardiman G.
Pharmacogenomics. 2010 Apr;11(4):481-5.
[Recent progress in mycobacteriology].
Okada M, Kobayashi K.
Kekkaku. 2007 Oct;82(10):783-99. Japanese.
New science-based endpoints to accelerate oncology drug development.
Kelloff GJ, Sigman CC.
Eur J Cancer. 2005 Mar;41(4):491-501. Epub 2005 Jan 22. Review.
Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases.
Cho CH, Nuttall ME.
Expert Opin Ther Targets. 2002 Dec;6(6):679-89. Review.
Cell microarrays in drug discovery.
Castel D, Pitaval A, Debily MA, Gidrol X.
Drug Discov Today. 2006 Jul;11(13-14):616-22. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on